Mitch Gold and his struggling biotech Dendreon ($DNDN) can't catch a break since disappointing Wall Street with lackluster sales of the prostate cancer drug Provenge. TheStreet announced Gold was voted this year's worst chief executive in a poll that drew 1,800 votes. It's more proof of how a disappointing drug launch can quickly change the fortunes of a biotech CEO; Gold was voted as TheStreet's best chief last year after his company gained the first-ever FDA nod for a cancer vaccine. Article